Business Wire10.19.17
BioCardia Inc., a developer of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure, has been issued a U.S. patent for steerable endoluminal devices and methods.
BioCardia CEO Peter Altman, PhD stated, “This new patent provides greater protection for our Morph vascular navigation products, which have broad clinical application to enable complex interventional procedures. Moving forward, we will continue to pursue our patent strategy of protecting active programs where we are investing our resources.”
The Morph steerable, thin-walled catheter shaft technology is designed to navigate through tortuous anatomy, customize the shape of the catheter to the patient's anatomy and their clinical needs during a procedure, and offer significant back-up support once positioned. To date, Morph products have been used in more than 10,000 clinical procedures worldwide.
BioCardia Inc., headquartered in San Carlos, Calif., is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the company’s biotherapeutic product candidates in clinical development. The company's current products include the Helix transendocardial delivery system and the Morph steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.
BioCardia CEO Peter Altman, PhD stated, “This new patent provides greater protection for our Morph vascular navigation products, which have broad clinical application to enable complex interventional procedures. Moving forward, we will continue to pursue our patent strategy of protecting active programs where we are investing our resources.”
The Morph steerable, thin-walled catheter shaft technology is designed to navigate through tortuous anatomy, customize the shape of the catheter to the patient's anatomy and their clinical needs during a procedure, and offer significant back-up support once positioned. To date, Morph products have been used in more than 10,000 clinical procedures worldwide.
BioCardia Inc., headquartered in San Carlos, Calif., is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP and CardiALLO cell therapies are the company’s biotherapeutic product candidates in clinical development. The company's current products include the Helix transendocardial delivery system and the Morph steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.